Proteomics International Laboratories (ASX:PIQ) may face delays in executing its direct-to-consumer strategy in commercializing its diagnostic tests for diabetes, endometriosis, and esophageal cancer, according to a Tuesday note from Euroz Hartleys.
The company has reaffirmed its plan for the US launch in the first half of 2025 of its lead diagnostic test PromarkerD for detecting diabetic kidney disease, adding that it remains on track for an Australian launch of the test in the first quarter of 2025.
Euroz Hartleys believes that the commercialization could take longer than expected, citing potential execution risks with the direct-to-consumer pathway.
Euroz Hartleys notes that the partners in place in other territories have only covered the pre-launch of PIQ's tests in smaller markets.
The firm maintained a hold rating and price target of AU$0.72 on Proteomics.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。